Barinthus Biotherapeutics (BRNS) Corporate Presentation summary

Mission and strategic focus

• Advancing next-generation immunotherapies for autoimmunity and inflammatory diseases using proprietary SNAP-TI platform.

• Clinical programs in infectious disease and oncology leveraging viral vector platforms, seeking partner support for advancement.

• Emphasis on restoring immune tolerance and reducing inflammation in I&I diseases.

SNAP-TI platform and scientific approach

• SNAP-TI is a differentiated, antigen-specific immune tolerance platform designed for broad antigen coverage and patient-friendly administration.

• Promotes Treg/Teff ratio increase, restoring immune homeostasis and reducing inflammation.

• Preclinical data show efficacy in multiple disease models, including multiple sclerosis and type 1 diabetes.

• Designed to address challenges of current I&I therapeutics, such as limited antigen coverage and tolerability.

Lead program: VTP-1000 for celiac disease

• VTP-1000 is a clinical-stage immunotherapy aiming to induce gluten tolerance by modulating Treg and Teff cells.

• Ongoing Phase 1 trial (AVALON) evaluating safety and tolerability, with single ascending dose data expected in Q3 2025.

• Preclinical data show VTP-1000 traffics to lymph nodes, reduces inflammatory cytokines, and is recognized by celiac patient T cells.

• Celiac disease represents a large market with no FDA or EMA approved treatments and high unmet need.